U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions - 11/20/2020
  1. News & Events for Human Drugs

Webcast | Virtual

Event Title
Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions
November 20, 2020


Date:
November 20, 2020

 

This webinar, and the guidance it accompanies, is intended to help applicants submitting an abbreviated new drug application (ANDA) seeking approval of a generic drug to identify:

  • a reference listed drug (RLD), i.e., a previously approved drug product on which an applicant relies in seeking approval of a generic drug;
  • a reference standard, i.e., the previously approved drug selected by FDA that an applicant must use in conducting any in vivo bioequivalence testing required to support approval of its ANDA; and
  • the basis of submission for the ANDA.

FDA PRESENTER
James Hanratty, JD
Regulatory Counsel
Division of Policy Development (DPD) | Office of Generic Drug Policy (OGDP) | Office of Generic Drugs (OGD) | Center for Drug Evaluation and Research (CDER)

RESOURCES

Back to Top